Eli Lilly and Company (NYSE:LLY) Shares Bought by Trifecta Capital Advisors LLC

Trifecta Capital Advisors LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 0.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,947 shares of the company’s stock after acquiring an additional 131 shares during the period. Eli Lilly and Company makes up approximately 4.1% of Trifecta Capital Advisors LLC’s investment portfolio, making the stock its 8th largest position. Trifecta Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $19,444,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Capital Planning LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $6,916,000. M&G Plc acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $8,896,000. BTC Capital Management Inc. bought a new position in Eli Lilly and Company during the 1st quarter worth $1,432,000. Finally, High Net Worth Advisory Group LLC increased its stake in Eli Lilly and Company by 1.4% during the 1st quarter. High Net Worth Advisory Group LLC now owns 4,919 shares of the company’s stock worth $3,827,000 after acquiring an additional 67 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Jefferies Financial Group increased their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Finally, Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $986.00.

Eli Lilly and Company Price Performance

LLY stock opened at $917.18 on Friday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The company has a market capitalization of $871.69 billion, a P/E ratio of 135.08, a PEG ratio of 2.79 and a beta of 0.42. The company has a fifty day moving average price of $920.70 and a 200-day moving average price of $856.27.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, equities analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.